Log In
BCIQ
Print this Print this
 

SQ109

  Manage Alerts
Collapse Summary General Information
Company Sequella Inc.
DescriptionDiamine antibiotic that inhibits cell wall synthesis
Molecular Target Not available
Mechanism of ActionCell wall synthesis inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsTreat multi-drug resistant tuberculosis (MDR-TB); Treat pulmonary tuberculosis (TB); Treat tuberculosis (TB)
Regulatory Designation U.S. - Fast Track (Treat pulmonary tuberculosis (TB));
U.S. - Orphan Drug (Treat tuberculosis (TB));
EU - Orphan Drug (Treat tuberculosis (TB))
PartnerInfectex Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$50.0M

0

0


 Deals Details
Get a free BioCentury trial today